FDA Just Approved ‘Smart Pill’ Antidepressant So Gov’t Can Track You As They Force Medicate You
The Food and Drug Administration (FDA) recently approved what may be the world’s first “smart pill.” Abilify MyCite, (aripiprazole) a “pill with a sensor that digitally tracks if patients have ingested their medication” was approved for sale and distribution by the FDA in mid-November. Now, a month after the drug’s approval, several of the world’s leading medical doctors are questioning the ethics surrounding the controversial drug.
Presumably using “compliance” with taking prescribed medicines as justification, the drug, “has an ingestible sensor embedded in the pill that records that the medication was taken.” Abilify MyCite was “approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.” Abilify is a selective serotonin reuptake inhibitor (SSRI), a class of drugs which, by law, must contain the following black box warning label for consumers. That black box warning label reads:
• Elderly patients with dementia-related psychosis treated with antipsychotic drugs are
at an increased risk of death. ABILIFY is not approved for the treatment of patients with
dementia-related psychosis. (5.1)
• Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal
thoughts and behaviors. (5.3)